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Abstract Neutrophils and mononuclear cells are implicated in the pathogenesis of several inflammatory conditions
including chronic obstructive pulmonary disease (COPD). Neutrophil-derived serine proteases, such as cathepsin G
(CG) and neutrophil elastase (NE), may interact with mononuclear cells via protease-activated receptors (PARs), which
are seven-transmembrane G protein-coupled receptors activated by proteolytic cleavage of the extracellular N-termi-
nus, andwhich, on activation, induce therelease of severalmediators andcytokines.We determinedwhether CGandNE
could affect PAR-1expression and function inmononuclear cells.Human bloodmononuclear cells were isolated from 20
healthydonors.Surface andintracellularreceptorexpression andcalciummobilisation (using the calciumchelator,FLUO3-
AM) were studied by fluorescence-assisted cell sorting (FACS analysis). Positive controls, i.e. thrombin (0.1^100mU/ml)
and the PAR-1-activating peptide SFLLRN (100 mM), induced a rapid and transient internalisation of PAR-1 inmonocytes
and lymphocytes.CG but not NE had a similar effect. By contrast, in monocytes intracellular calcium mobilisation was
induced by thrombin and SFLLRNbut not by CG and NE.Thus,CG can induce intracellular PAR-1sequestrationwithout
activation of the receptor, andmay act as an antagonist andprevent subsequent activation of PAR-1inmononuclear cells.
These findingsmaybe of relevance to the pathogenesis of COPD.r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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£ux.INTRODUCTION
Protease-activated receptors (PARs, PAR-1 to PAR-4)
are seven-transmembrane G protein-coupled receptors
that are activated through unique mechanism of site-
speci¢c cleavageby serineproteases (1).Themain agonist
of PAR-1, PAR-3 and PAR-4 is thrombin, while trypsin is
the most potent agonist of PAR-2 (1^3). Several PAR-
mediated e¡ects may be relevant in airway diseases:
PAR-1and PAR-2 have been shown to regulate broncho-
constrictor responses of human airways and release of
several cytokines and mediators by monocytes/macro-
phages, mast cells, endothelial and epithelial cells, ¢bro-
blasts and smoothmuscle cells (4^10).
The site of cleavage of PARs by serine-proteases is lo-
cated on the NH2-terminal exodomain of the receptor;
cleavageyields a newNH2 terminus, which acts as a teth-
ered ligand and binds to, and activates the receptor (1).
Activation of these receptors is an irreversible phenom-Received 5 May 2002, accepted in revised form 8 August 2002
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from their G protein, internalised and degraded in lyso-
somes, while cell sensitivity to their agonists is restored
by new receptors which arise from an intracellular pool
(11). Some proteases can cleave PARs at sites located
downstream of the tethered ligand, or cleave the teth-
ered ligand itself, thereby rendering the receptor inactive
and/or unresponsive to subsequent enzymatic activation
(1). Neutrophil elastase (NE) is one of the enzymes that
may inhibit activation of PAR-1by this mechanism, while
cathepsin G (CG), another neutrophil serine protease,
can both activate PAR-1by cleavage at the thrombin site
and inactivate it by downstream cleavage (1).
PARs are widely distributed and are expressed in sev-
eral cell types (1) including monocyte/macrophages and
lymphocytes. Therefore, we hypothesised whether
these cells could be a¡ected by neutrophil serine pro-
teases through PAR-1cleavage. Such an interaction could
occur in chronic in£ammatory conditions such as chronic
obstructive airways disease in which there is accumula-
tion ofmonocytes/macrophages,T lymphocytes andneu-
trophils, and in which products of activated neutrophils
such as NE and CGmay play a major role (12,13).We de-
termined the e¡ects of NE and CG on the expression
PAR-1ACTIVATIONBYNEUTROPHILENZYMES 229and function of PAR-1inmonocytes and lymphocytes, by
using £uorescence-assisted cell sorting (FACS) to exam-
ine the internalisation and recycling of receptors and
their coupling to intracellular calcium release.
MATERIALANDMETHODS
Isolation of peripheral bloodmonocytes
Peripheral venous blood from 20 healthy non-smoking
volunteers was mixed with acid-citrate dextrose
(1:6 vol/vol) and sedimented on dextran (6% in 0.9%
NaCl) for 40min. Mononuclear cells were separated by
Ficoll-Hypaque density centrifugation. Cells were
washed twice with Hanks’ balanced salt solution (HBSS)
andplated at a concentration of1106monocytes/1ml in
12-wellplates.Cell viability was consistently496% as as-
sessed by trypan blue exclusion. At 24h, cells were used
to study the e¡ect of agonists on calcium £ux and PAR-1
surface expression.
Regulation of PAR-1expression
PAR-1 expression was assessed by FACS. Two prelimin-
ary experiments were performed to determine the
time-course of PAR-1 expression: ¢rstly, we assessed
the kinetics of the decrease in PAR-1expression after in-
cubationwith SFLLRN (PAR-1agonist,100mM) for10, 30,
60, 120, and 240min (n=3 for each condition). Secondly,
we studied the kinetics of PAR-1 re-appearance: cells
were ¢rst incubatedwith SFLLRNduring1hbeforebeing
washed and incubated in SFLLRN-freemedium for 0, 2, 4
or 24h (n=3 for each condition).
To study the e¡ects of agonists and enzymes, cells
were incubated for 1 h in the presence of medium alone
or containing the tested agent.Optimal dosage of tested
agents was ¢rst assessed by dose^response experi-
ments with concentrations of 1, 10 and 100mM for
SFLLRN; 1, 10 and 100U/ml for thrombin; 109, 108 and
107M forCG; 108,107, and106M forNE; and1,10 and
100mMfor PAR-1antagonistpeptide (H^Met^Ser^Arg^
Pro ^Ala^Cys^Pro ^Asn^Asp^Lys^Tyr^Glu^OH, ne-
gative control) (N=3 per condition). The e¡ect of the
optimal dosage of each agent was then con¢rmed in
three additional samples.
After incubation, cells were harvested by scraping,
washed in1ml HBSS, and re-suspended in100ml Dubelc-
co’s PBSwithout calcium andmagnesium. In order to as-
sess surface expression of PAR-1, cells were incubated
during 30minwith anti-PAR-1phycoerythrin (PE)-conju-
gated antibody (7:100 vol/vol).Two antibodieswere used:
SPAN12, which identi¢es intact receptors only, and
WEDE15, which identi¢es both intact and cleaved recep-
tors. To identify monocytes, cells were also simulta-
neously incubated with £uorescein isothyocyanate
(FITC)-conjugated mouse monoclonal anti-CD14 mono-clonal antibodies (7:100).To assess the intracellular pool
of PAR-1, cells were ¢rst incubated with anti-CD14 anti-
body before being permeabilised using DAKO IntraStain
Kit (Cambridge, U.K.), and incubated with anti-PAR-1
SPAN12 or WEDE15 antibodies. After a ¢nal wash, cells
were re-suspended in £ow cytometry bu¡er (FACSFlow,
Becton Dickinson, San Jose, CA, U.S.A.) containing 1%
paraformaldehyde, and £uorescence was measured by a
FACScan £ow cytometer (Becton Dickinson, San Fran-
cisco,CA,U.S.A.).Forward scatter (FSC) and side scatter
(SSC) characteristics were recorded on a linear scale
while £uorescence at 530nm (FL1 channel) and 670nm
(FL2 channel)wererecordedon a logarithmic scale. Lym-
phocytes andmonocytes were identi¢ed using both the
FSC^SSC and intensity of CD14 staining as recorded on
the FL1channel, inwhich emissions from FITC conjugates
are recorded. To assess PAR-1 expression, we analysed
the percentage of gated cells and the mean (MFI) and
speci¢c (SFI) £uorescence intensity of each cell type in
the FL2 histograms, since PE-conjugates emit in the FL2
channel. A PE-conjugated mouse IgG2a with no known
reactivity to human antigens was used as isotype con-
trol. Speci¢c £uorescence intensity was calculated as fol-
lows: SFI= sample MFI ^ isotype control MFI.
Measurement of intracellular calcium
mobilisation
Measurement of intracellular calcium mobilisation was
performedusing £owcytometry with Fluo3/AM, a £uor-
escent calcium chelator which enters cells where it is
metabolised tomembrane-impermeant Fluo3.The spon-
taneous £uorescence of Fluo3 increases after calcium
chelation and can be read at 530 nm (FL1 channel) after
excitation at 488nm. Cells were ¢rst incubated during
15min in RPMI medium containing 2mM of Fluo3/AM,
harvested by scraping and washed twice in HBSS before
beingresuspendedin 0.5mlofphenol red-freeRPMI1640
in 5-ml rounded-bottom polypropylene tubes (Falcon).
Thirty minutes later, measurements were performed
using a FACScan £ow cytometer (Becton Dickinson);
after two reproducible (o5% variation) baseline mea-
surements, tested agentswere addedat the optimal con-
centration that induced a decrease in receptor
expression (SFLLRN,100mM; thrombin,100U/ml; cathe-
psinG,108M; neutrophil elastase,106M; and PAR-1 an-
tagonist peptide, 100 mM).Then, £uorescence in the FL1
channel was recorded repeatedly until baseline values
were reached again.When no response was observed,
recordings were repeated during 1h. At least 5000
events were recorded for each measurement and four
experiments were performed for each tested agent. For
the analysis, a FSC^SSC dot plot was used to gate on
monocytes and lymphocytes, and changes of mean FL1
£uorescence intensity (MFI) in each gatewere analysed.
FIG. 1. Time course of PAR-1 surface expression after incuba-
tion with 100 mM SFLLRN. Surface expression is assessed by
FACS analysis using PE-conjugated anti-PAR-1 antibodies. Data
are shown as mean7SEM of triplicate experiments. Panel A:
time-course of decrease in PAR-1 surface expression after the
beginning of incubation; a maximal decrease is observed at
10min in lymphocytes and at 1h in monocytes. Panel B: time-
course of PAR-1 reappearance after removal of SFLLRN from
the medium and washing of cells.Baseline surface expression is
restored at 2 h inmonocytes and lymphocytes.
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Complete monocyte/macrophage culture medium was
RPMI-1640 (ICN-Flow, HighWycombe, U.K.) containing
10% heat-inactivated fetal calf serum (Sera Lab,Crawley,
U.K.), 2mM L-glutamine (ICN-£ow), and penicillin-strep-
tomycin (100U/ml ^ 100ml, ICN £ow). Culture plates
were from Falcon (London, U.K.). PAR-1 agonist peptide
SFLLRN (PAR-1) was from Bachem (Sa¡ron Walden,
U.K.). Thrombin (1000 NIH Units/ml) was from Sigma,
elastase (150U/mg of protein) was from Calbiochem
(Nottingham, U.K.), and cathepsin G (2^4U/mg) was
from ICN-Flow. Anti-PAR-1 antibodies were from Santa
Cruz Biotechnology (Calne, U.K.). FITC-conjugated
monoclonal anti-CD14 mouse IgG2a was from Sigma.
Fluo3/AM was from Alexis corporation (Nottingham,
U.K.).
Data analysis
Results are expressed as mean7SEM. Comparisons
were performed using non-parametric tests. A thresh-
old of P40.05 was considered for statistical signi¢cance.
All statistics were performed using SPSS 7.5 software
(SPSS Inc.,Chicago, IL,U.S.A).
RESULTS
Regulation of PAR-1expression
PAR-1was expressed by 44% of lymphocytes and 28% of
monocytes atbaseline (P40.01) but SFIwas similar in the
two cell types. The decrease in PAR-1 expression after
exposure to SFLLRN (100mM) was maximal at 10min in
lymphocytes and at 60min in monocytes (Fig 1).There-
fore, subsequent experiments were studied after 1h in-
cubation. PAR-1 surface expression returned to baseline
levels 2 h after cessation of exposure in bothmonocytes
and lymphocytes (Fig.1).
The surface expression of intact and total (intact+-
cleaved) PAR-1 in lymphocytes and monocytes was
markedly decreased after incubation in the presence of
SFLLRN (concentration for maximal e¡ect: 100mM),
thrombin (concentration for maximal e¡ect: 100U/ml),
CG (concentration for maximal e¡ect: 108M) while
elastase (concentration up to106M) and PAR-1 antago-
nist peptide (100mM) had no signi¢cant e¡ect (Fig 2). In
parallel, the intracellular expression of intact and total
PAR-1 was not a¡ected by SFLLRN, thrombin and CG
(data not shown).
Intracellular calciummobilisation
Inmonocytes, SFLLRNand thrombinbutnotCGandNE
elicited a transient intracellular calcium £ux (Fig 3).We
could not obtain reproducible results in lymphocytes,which is likely due to an insu⁄cient sensitivity of the
FACSmethod for assessing calciummobilisation in these
cells.
DISCUSSION
We have shown that both monocytes and lymphocytes
express PAR-1, and that this expression is markedly re-
duced by exposure to known PAR-1 agonists such as
thrombin and the peptide SFLLRN.Of the two neutro-
phil serine proteases, CG but not elastase also caused a
reduction in PAR-1receptor expression in both lympho-
cytes and monocytes. Reduction of PAR-1 expression
after exposure to SFLLRN was maximal at 1h; expres-
sion recovered 2h after washing-o¡ of the peptide but
FIG 2. Decrease in total (intact+cleaved) PAR-1 surface ex-
pressioninlymphocytes (Panel A) andmonocytes (Panel B) after
incubation in the presence of SFLLRN (100 mM), thrombin
(100U/ml),CG (50 nM), butnotelastase (100 nM) and PAR-1 an-
tagonist peptide (100 mM). Surface expression is assessed FACS
analysis using PE-conjugated anti-PAR-1 antibodies. Similar re-
sultswere foundwiththe antibody thatbinds to intactreceptors
only. A representative result in monocytes is shown in Panel C.
SFLLRN, thrombin and cathepsin G induce a decrease in MFI
(disappearanceofthepeakofeventsobservedat about102 £uor-
escence units with the control solution). Data are shown as
mean7SEMof sixexperiments.*Po0.05.
FIG 3. Calciummobilisation inmonocytes after PAR-1 stimula-
tion. Top panel shows the e¡ects of thrombin (100U/ml),
SFLLRN (100 mM),CG (50 nM) and elastase (100 nM) on mean
£uorescence intensity (MFI, expressed as % of baseline) in cells
incubated with FLUO3-AM, a calcium chelator that becomes
£uorescent after binding to calcium. Results are expressed as
mean7SEM of four experiments. A representative experiment
is shown on the bottompanel.The grey line represents baseline
£uorescence in the FL1 channel (reading at 530 nm after excita-
tion at 488 nm) inmonocytes gated on in the FSC^SSCdot plot.
The black line was recorded 20 s after exposure to100U/ml of
thrombin; the increase in £uorescence (right shift of the histo-
gram) indicates anincrease in intracellular calcium.
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release data indicate that both cathepsin and elastase do
not induce intracellular calcium release, despite the abil-
ity of CG to induce internalisation of PAR-1 receptors.
However, thrombin and the PAR-1 agonist, SFLLRN,
both induce calciummobilisation, thrombinbeing amore
potent e¡ector in this respect. Altogether, these data in-
dicate that CG could act as an antagonist at the PAR-1
receptor.Peripheral blood lymphocytes and monocytes have
both been shown to express PAR-1 mRNA (14,15).
Although the functional signi¢cance of PAR-1 activation
in these cells is not known, this receptor seems to parti-
cipate in in£ammatory phenomena: in monocytes, the
activation of PARs induces the release of several chemo-
tactic or pro-in£ammatory cytokines including mono-
cyte chemotactic protein-1, IL-1b, TNF-a and IL-6 [1,15^
18]. Since lymphocytes, monocytes and neutrophils are
themain in£ammatory cells involved in the pathogenesis
of airway in£ammation and damage in chronic obstruc-
tive pulmonary disease (COPD) (12,13), our hypothesis
232 RESPIRATORYMEDICINEwas that neutrophil serine proteases could modulate
mononuclear cells activation through e¡ects on PAR-1.
Studies with PAR-1antagonists and cross-desensitisation
experiments remain to be perfomed to test this possibi-
lity. Protease inhibitors would not be suitable in this re-
spect since they do not avoid non-speci¢c enzymatic
e¡ectsmediated by pathways other than PAR-1.
NE and CG are both products of activated neutro-
phils, which are recruited to and activated in the airways
of COPD patients (12,19), and produce increased
amounts of NE; this enzyme is involved in the develop-
ment of emphysema through its e¡ect on the extracellu-
lar matrix (20,21) and induces goblet cell degranulation
(22,23), plasma protein extravasation (24), epithelial cell
detachment, and production of IL-8 and PGE2 by epithe-
lial cells (21).CG also causesmucus secretion and epithe-
lial cell detachment (21,25) and induces airway
hyperresponsiveness (26).Our data indicate that neutro-
phil serine proteases are not signi¢cant activators of in-
tracellular calciummobilisation inmonocytes despite the
clear expression of functional PAR-1 by these cells and
the potential ability of CG to cleave this receptor at the
thrombin activating site.Conversely,CGappears capable
of causing intracellular sequestration of PAR-1receptors
in both monocytes and lymphocytes without receptor
activation, which illustrates the dissociation between
these two events. This may lead to cellular desensitisa-
tion, thereby preventing further PAR-1 activation by
thrombin or CG itself.
Onepotential limitation of our studyof PAR-1 interna-
lisation is that, in preliminary studies, we assessed the
kinetics of this phenomenon only with PAR-1 agonist
peptide SFLLRN; but this may di¡er with CG, elastase
or thrombin. However, these agonists act much more
quickly than the agonist peptides, which are are also less
potent.The reason for this is that the 3D conformation
of the uncleaved receptor, in which the unaltered NH2
terminus partially masks the ligand binding site, makes
it less accessible. In addition, inbothmonocytes and lym-
phocytes, a signi¢cant e¡ect was observed between
10min and 4h after SFLLRN addition, making it unlikely
to miss an e¡ect of enzymatic agonists at 1h. Finally, the
lack of intracellular calcium mobilisation that we ob-
served after stimulationwith CGis unlikely to be related
to a di¡erence in kinetics since all samples were studied
up to 1h after addition of studied agents, the e¡ect of
SFLLRN and thrombin being observedwithin 5min.
PAR-1 is present on both the plasma membrane and
intracellularly. There is a substantial intracellular pool,
fromwhich new receptors are translocated to the plas-
ma membrane to restore cell sensitivity to PAR-1 ago-
nists (1). Activated cell surface PAR-1 is known to be
rapidly internalised and then sorted out predominantly
to lysosomes (27).This is in agreementwith the decrease
in PAR-1surface expression, but not in global cellular ex-
pression that we found after exposure to thrombin andthe peptide SFLLRN, which both induced cell activation
as assessed by intracellular calciummobilisation. Recep-
tor internalisation,which ismediatedbyphosphorylation
of the cytoplasmic tail of the receptor, has also been
found to occur independently of activation, either spon-
taneously (as part of a permanent tra⁄cking between
plasma membrane and intracellular pool) or after non-
activating cleavage (11,27^31). Such a phenomenon is con-
sistent with our ¢ndings with CG, which induced a de-
crease in surface PAR-1 expression in the absence of
calcium signal.CG can cleave PAR-1at the thrombin site
Arg41kSer42 but also at two non-activating sites located
downstream to the thrombin site, i.e., Phe43kLeu44 and
Phe55kTryp56 [32]. This non-activating cleavage leads to
removal of the tethered ligand and generates an unre-
sponsive receptor that is internalised and degraded
(27).Thus, our ¢ndings with CGmay re£ect a predomi-
nance of non-activatingover activating cleavage of PAR-1
in human monocytes, subsequently rendering the cell
unresponsive to activation by CG or thrombin.This is in
agreement with the data of Molino et al. in platelets and
endothelial cells, in which activating cleavage was pre-
vented by removal of the tethered ligand through down-
stream cleavage by CG at the Phe55kTryp56 site (32).
We did not ¢nd any evidence of PAR-1 internalisation
after exposure to elastase, which also did not induce any
detectable calciummobilisation.However, a non-activat-
ing PAR-1 cleavage site by elastase has been identi¢ed
(33). Our ¢ndings suggest that such a cleavage either
does not occur (e.g. because the cleavage site is not su⁄-
ciently accessible due to molecular conformation of sur-
face PAR-1), or does not induce the signalling which is
required to produce receptor internalisation (i.e. phos-
phorylation of intracellular carboxy-terminal tail).
In conclusion, our data indicate that the neutrophil en-
zymes,CG andNE, do not activatemononuclear in£am-
matory cells through PAR-1cleavage.
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